Abstract: This present disclosure provides a kit and method for detecting at least one KANSARL fusion transcript from a biological sample from a subject. The kit comprises at least one of the following components: (a) at least one probe, wherein each of the at least one probe comprises a sequence that hybridizes specifically to a junction of the at least one KANSARL fusion transcript; (b) at least one pair of probes, wherein each of the at least one pair of probes comprises: a first probe comprising a sequence that hybridizes specifically to KANSL1; and a second probe comprising a sequence that hybridizes specifically to ARL17A; or (c) at least one pair of amplification primers, wherein each of the at least one pair of amplification primers are configured to specifically amplify the at least one KANSARL fusion transcript.

Abstract: This present disclosure generally relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure provides a computerized method for detecting fusion transcripts from RNA-seq data and provides the fusion transcripts identified thereby in human cancers. Compositions and methods for identifying the fusion transcripts are also provided.